InvestSMART

PharmX Technologies Limited (ASX:PHX)

ALERT: Price-sensitive ASX Announcement for PHX
Current share price for PHX : $0.100 -0.045 (-31.03%)+
Announcement
Release
25 Feb 2026 8:32AM
Price at Release
$0.145
Full Release
download
Summary
PharmX Technologies Limited, trading as PHX, reported a 3% revenue growth for the half-year ending FY26, despite strategically pausing onboarding in anticipation of a new Marketplace launch. The launch resulted in record Marketplace GTV with substantial growth. The company maintained positive operating cash flows, closing with $3.2 million in cash as of December 31, 2025. However, NPAT saw a significant decrease due to increased costs associated with strategic growth initiatives. A strategic partnership with Sigma | Chemist Warehouse was established, potentially allowing Sigma to acquire a significant equity stake. The company also reported strong growth in New Zealand and robust supplier integration, even as operational costs rose due to expansion efforts. Gateway and Marketplace revenues increased notably, reflecting the company's continued investment and growth trajectory.
Key Points
  • Pharmx Technologies reported a 3% revenue growth in H1 FY26 despite a strategic pause to onboarding ahead of a new Marketplace launch.
  • The launch of the Pharmx Marketplace in November 2025 resulted in record Marketplace Gross Transaction Value (GTV), with a 68% increase from its previous peak and 79% month-over-month growth.
  • Positive operating cash flows were reported, with a closing cash balance of $3.2 million as of December 31, 2025.
  • Net Profit After Tax (NPAT) decreased by 430% compared to H1 FY25, primarily due to increased costs related to strategic growth initiatives including personnel, technology, and marketing expenses.
  • Pharmx has established a strategic partnership as a preferred EDI partner with Sigma
  • Chemist Warehouse, which includes a multi-year strategic alliance and the possibility for Sigma to acquire up to a 19.9% equity stake in Pharmx.
  • Significant growth in New Zealand operations, with a 54% increase in revenue from the region.
  • The company experienced strong supplier momentum, onboarding 19 new suppliers in H1 FY26 despite an onboarding pause prior to the Marketplace launch.
  • Operational costs increased by 25%, attributed to the expansion and launch of new business initiatives.
  • EBITDA for H1 FY26 was positive, despite a decrease from the previous year, reflecting continued investment in growth.
  • Pharmx's Gateway revenue increased by 5% compared to H1 FY25, and Marketplace revenue saw a 24% increase.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.